文献速递膀胱癌与上尿路尿路上皮癌

诊室激光凝固术对比经尿道膀胱肿瘤电切术治疗Ta期低级别膀胱肿瘤:12个月随访随机临床试验

In-Office Laser Coagulation of Ta Bladder Tumor Compared With Transurethral Resection of Bladder Tumor: 12 Months Follow-Up Randomized Clinical Trial.
PubMed 文献 · J Urol · 2025-12-29

12个月无复发生存率(RFS)激光组43.5%对比TUR-BT组43.0%,差异-0.5%(单侧95%CI上限12%),满足15%非劣效界值;

要点

  • 诊室激光凝固术12个月RFS非劣效于TUR-BT,差异-0.5%(单侧95%CI上限12%)。
  • 诊室局麻激光凝固术可作为复发性Ta低级别膀胱肿瘤的安全高效治疗选择。

核心结论

  • 诊室激光凝固术治疗复发性Ta低级别膀胱肿瘤在12个月RFS上非劣效于TUR-BT。
  • 该技术安全、高效,可作为复发性Ta低级别膀胱肿瘤的治疗选择。

研究设计与样本

  • 前瞻性、随机、非劣效性临床试验,2016–2022年在丹麦一家医院开展。
  • 干预为诊室局麻下980nm激光凝固术(PC-BT),对照为全麻下标准TUR-BT。
  • 主要终点12个月RFS,非劣效界值为15%绝对差异。

主要发现

  • 12个月RFS:PC-BT组43.5%,TUR-BT组43.0%,差异-0.5%(单侧95%CI上限12%),满足非劣效。
  • 延长随访期间两组各观察到1例分期进展。

关键数值与推荐

  • 非劣效性判定标准为12个月RFS绝对差异15%。
  • 12个月RFS差异-0.5%,单侧95%CI上限12%,低于15%界值。

临床怎么用

  • 对复发性Ta低级别膀胱肿瘤,可考虑诊室局麻下激光凝固术替代TUR-BT。
  • 该术式可在诊室完成,避免全麻和住院,可能降低治疗负担和成本。

局限性

  • 研究仅在丹麦单家医院开展,外推性需进一步验证。
  • 原文未报告样本量计算、具体不良事件及成本数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ta low-grade bladder tumors, accounting for 45% of new bladder cancer cases, have considerable risk of recurrence but low risk of progression. Traditionally, treatment is burdensome and costly. Office-based laser coagulation of Ta low-grade bladder tumors is efficient, tolerable, and safe; however, long-term outcomes need to be determined. The primary objective of this study was to determine whether in-office laser coagulation of recurrent Ta low-grade bladder tumor is noninferior to standard transurethral resection of bladder tumor (TUR-BT) regarding 12-month recurrence-free survival (RFS). MATERIALS AND METHODS: Prospective, randomized, noninferiority clinical trial, performed in a hospital setting in Denmark between 2016 and 2022. Three hundred consecutive patients with recurrent Ta low-grade bladder tumor participated. Laser (photograph) coagulation of the bladder tumor (PC-BT) was performed with a 980 nm laser under local anesthesia in an office setting and compared with gold standard TUR-BT under general anesthesia. Primary outcome, 12-month RFS, was analyzed with noninferiority criterion of 15% absolute difference. Secondary outcomes included long-term RFS and stage progression. RESULTS: RFS at 12 months was 43.5% after PC-BT and 43.0% after TUR-BT; difference of -0.5% compared with PC-BT (one-sided 95% CI upper bound 12%), meeting noninferiority requirement. During extended follow-up (median 47.9 months), RFS was not significantly different between groups (P = .25) and only one case of stage progression was observed in each group. CONCLUSIONS: Office-based laser photograph coagulation of bladder tumor is noninferior to TUR-BT regarding 12-month RFS and is a safe, efficient treatment for recurrent Ta low-grade bladder tumors.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Pedersen GL, Mogensen K, Rosthøj S, et al. In-Office Laser Coagulation of Ta Bladder Tumor Compared With Transurethral Resection of Bladder Tumor: 12 Months Follow-Up Randomized Clinical Trial. J Urol. 2025. PMID: 41461083. doi:10.1097/JU.0000000000004918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。